Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CEPT1 | Q9Y6K0 | 5/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | AGPAT2 | O15120 | 2/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 8/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | STAT3 | P40763 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6084612 | 0.84 | MAPT (0.55) | CEPT1PTPN1AGPAT2MAPTTP53 | |
| SCHEMBL6085024 | 0.81 | CEPT1 (0.46) | CEPT1AGPAT2MAPTRXFP1TP53 | |
| SCHEMBL6085967 | 0.79 | CEPT1 (0.51) | CEPT1AGPAT2MAPTRXFP1SLC6A3 | |
| SCHEMBL6085859 | 0.79 | CEPT1 (0.51) | CEPT1AGPAT2MAPTRXFP1TP53 | |
| SCHEMBL6086666 | 0.79 | CEPT1 (0.49) | CEPT1AGPAT2MAPTRXFP1TP53 | |
| SCHEMBL6086300 | 0.78 | CEPT1 (0.47) | CEPT1AGPAT2MAPTRXFP1TP53 | |
| SCHEMBL6084017 | 0.76 | CEPT1 (0.52) | CEPT1AGPAT2MAPTRXFP1TP53 | |
| SCHEMBL6084877 | 0.76 | RAB9A (0.52) | CEPT1MEN1HPGDKMT2ASMN1; SMN2 | |
| SCHEMBL6085752 | 0.76 | MAPT (0.48) | CEPT1AGPAT2MAPTKDM4EMEN1 | |
| SCHEMBL6085513 | 0.76 | CEPT1 (0.58) | CEPT1AGPAT2MAPTRXFP1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7105535-B2 | Oxazolyl-pyrazole derivatives as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2006-09-12 | — | — | US | claimed |
| EP-1377589-B1 | OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PHARMACIA ITALIA SPA (IT) | 2005-09-07 | — | — | EP | claimed |
| US-20040180881-A1 | Oxazolyl-pyrazole derivatives as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2004-09-16 | — | — | US | claimed |
| US-7105535-B2 | Oxazolyl-pyrazole derivatives as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2006-09-12 | — | — | US | disclosed |
| EP-1377589-B1 | OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PHARMACIA ITALIA SPA (IT) | 2005-09-07 | — | — | EP | disclosed |
| US-20040180881-A1 | Oxazolyl-pyrazole derivatives as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2004-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180881-A1 | Oxazolyl-pyrazole derivatives as kinase inhibitors | MAP3K15, MAP3K20, MAP3K3 | CEPT1 2798/4885PTPN1 344/4885AGPAT2 3284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.